Featuring perspectives from Dr Alexandra Drakaki, Ms Krisztina Emodi, Dr Terence Friedlander and Ms Margarita Huober, moderated by Dr Friedlander, including the following topics: Introduction: Basic Biology of Nonmetastatic Urothelial Bladder Cancer (UBC) (0:00) Systemic Therapy for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC) (13:35) Evolving Approach to Systemic Therapy for Cisplatin-Ineligible Patients with MIBC (37:13) Immune Checkpoint Inhibitors in Non-Muscle-Inva...
Jul 02, 2026•1 hr 30 min
Featuring perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics: Introduction (0:00) Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09) Therapeutic Approaches Targeting ALK and ROS1 — Dr Langer (31:56) CME information and select publications
Jun 30, 2026•50 min
Featuring perspectives from Dr Erika Hamilton, Dr Jane Lowe Meisel, Dr Joyce O'Shaughnessy and Dr Seth Wander, including the following topics: Introduction (0:00) Current and Future Management of HR-Positive, HER2-Negative Localized Breast Cancer — Dr Meisel(2:40) Optimizing First-Line Therapy for Patients with HR-Positive Metastatic Breast Cancer (mBC) — Dr Hamilton (36:57) Current and Future Role of Oral Selective Estrogen Receptor Degraders for Progressive HR-Positive mBC — Dr Wander (58:18) ...
Jun 29, 2026•1 hr 39 min
Featuring perspectives from Dr Courtney D DiNardo and Dr Harry Paul Erba, including the following topics: Introduction (0:00) Current Management Approaches for FLT3- and IDH-Mutated Acute Myeloid Leukemia (AML) — Dr DiNardo (9:44) Current and Future Role of Menin Inhibitors for Patients with AML — Dr Erba (32:07) CME information and select publications
Jun 28, 2026•52 min
Featuring perspectives from Dr Mrinal Gounder and Dr Richard F Riedel, including the following topics: Introduction (0:00) Desmoid Tumors — Dr Gounder (2:58) Soft Tissue Sarcoma — Dr Riedel (28:29) CME information and select publications
Jun 27, 2026•51 min
Featuring perspectives from Dr Jonathan Goldman and Dr Zofia Piotrowska, including the following topics: Introduction (0:00) Current Management of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Dr Goldman (0:38) Nonmetastatic EGFR-Mutated NSCLC, Exon 20 Insertion Mutations and Novel Agents — Dr Piotrowska (33:20) CME information and select publications
Jun 27, 2026•51 min
Featuring perspectives from Dr Kevin Punie and Dr Tiffany A Traina, including the following topics: Introduction: Where We Are; Where We're Heading (0:00) First-Line Treatment of BRCA Wild-Type Disease (9:14) First-Line Treatment of BRCA-Mutant Disease (38:48) Novel Approaches (47:49) CME information and select publications
Jun 26, 2026•54 min
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Muscle-Invasive and Muscle-Invasive Urothelial Bladder Cancer | Faculty Presentation 2: Muscle-Invasive Bladder Cancer — Thomas Powles, MBBS, MRCP, MD CME information and select publications
Jun 25, 2026•24 min
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Muscle-Invasive and Muscle-Invasive Urothelial Bladder Cancer | Faculty Presentation 1: Non-Muscle-Invasive Bladder Cancer — Ashish M Kamat, MD, MBBS CME information and select publications
Jun 25, 2026•19 min
Featuring perspectives from Dr Ashish M Kamat and Prof Thomas Powles, including the following topics: Introduction: Life After Radical Cystectomy (0:00) Muscle-Invasive Bladder Cancer — Prof Powles (9:15) Non-Muscle-Invasive Bladder Cancer — Dr Kamat (37:49) CME information and select publications
Jun 25, 2026•58 min
Featuring perspectives from Dr Dana M Chase, Ms Sarah Karpen, Dr J Alejandro Rauh-Hain and Ms Jaclyn Shaver, moderated by Dr Chase, including the following topics: Introduction: Biology of Endometrial Cancer (EC) (0:00) First-Line Therapy for Advanced or Recurrent EC (14:15) Potential Benefits of PARP Inhibition Combined with Immunotherapy in Advanced EC (35:13) Role of Lenvatinib/Pembrolizumab in the Management of Progressive Advanced EC (57:48) Other Nursing Considerations in the Care of Patie...
Jun 24, 2026•1 hr 28 min
Featuring perspectives from Dr Anthony M Hunter and Dr Abdulraheem Yacoub, including the following topics: Introduction (0:00) Systemic Mastocytosis — Dr Hunter (9:33) Myelofibrosis — Dr Yacoub (29:40) CME information and select publications
Jun 24, 2026•51 min
Featuring perspectives from Dr Neeraj Agarwal and Dr Alan H Bryce, including the following topics: Introduction (0:00) Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Dr Bryce (2:41) Other Available and Emerging Therapeutic Approaches — Dr Agarwal (35:16) CME information and select publications
Jun 23, 2026•50 min
Featuring perspectives from Dr Erika Hamilton and Dr Shanu Modi, including the following topics: Introduction (0:00) Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Dr Modi (0:58) Contemporary Management of HER2-Positive Metastatic Breast Cancer — Dr Hamilton (25:51) CME information and select publications
Jun 23, 2026•52 min
Featuring perspectives from Dr Kristen K Ciombor and Dr John Strickler, including the following topics: Introduction (0:00) Current and Future Role of Immune Checkpoint Inhibitors in the Management of Colorectal Cancer (CRC) — Dr Ciombor (3:58) Other Recent Advances in CRC Management — Dr Strickler (32:57) CME information and select publications
Jun 22, 2026•50 min
Featuring perspectives from Dr Adam M Brufsky and Dr Kevin Kalinsky, including the following topics: Introduction (0:00) Current and Future Role of TROP2-Directed Antibody-Drug Conjugates in Therapy for Triple-Negative Breast Cancer (TNBC) — Dr Brufsky (5:08) Established Treatment Paradigm for Localized and Metastatic TNBC — Dr Kalinsky (35:20) CME information and select publications
Jun 20, 2026•49 min
Featuring an interview with Prof Bernd Kasper, including the following topics: Case: A woman in her early 30s develops a progressing desmoid tumor in her abdomen during pregnancy(0:00) Case: A woman in her late 30s with a painful small desmoid tumor in her rectus abdominus undergoes cryoablation (8:04) Case: A woman in her late teens with recurrent desmoid tumors in her right thigh undergoes multiple resections (13:58) Case: A woman in her mid 70s has a desmoid tumor causing erosion in her scapu...
Jun 20, 2026•24 min
Featuring perspectives from Dr Deborah K Armstrong and Dr David M O'Malley, including the following topics: Introduction (0:00) PARP Inhibitors and Strategies Targeting Folate Receptor Alpha in Advanced Ovarian Cancer — Dr Armstrong (4:37) Other Novel Agents and Strategies for the Treatment of Advanced Ovarian Cancer — Dr O'Malley (35:18) CME information and select publications
Jun 19, 2026•54 min
Featuring perspectives from Dr Yelena Y Janjigian and Dr Samuel J Klempner, including the following topics: Introduction (0:00) Role of Anti-PD-1/PD-L1- and CLDN18.2-Directed Antibodies in the Management of Gastroesophageal Cancers — Dr Klempner (5:52) Management of HER2-Positive Gastroesophageal Cancers — Dr Janjigian (28:20) CME information and select publications
Jun 19, 2026•51 min
Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics: Introduction (0:00) Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory Multiple Myeloma (R/R MM) — Dr Raje (4:30) Antibody-Drug Conjugates and Other Emerging Therapies for R/R MM — Dr Lee (28:33) CME information and select publications...
Jun 18, 2026•47 min
Featuring an interview with Prof Martin Reck, including the following topics: Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (0:00) Biology of small cell lung cancer and pharmacodynamics of systemic treatment (3:25) Considerations with maintenance therapy for ES-SCLC (9:31) Considerations with immunotherapy for ES-SCLC (13:12) Curability of SCLC with syste...
Jun 18, 2026•41 min
Featuring a slide presentation and related discussion from Prof Martin Reck, including the following topics: Overview of small cell lung cancer (SCLC) (0:00) First-line chemoimmunotherapy for extensive-stage SCLC (ES-SCLC) (3:50) Lurbinectedin as first-line maintenance therapy for ES-SCLC (12:36) Case: A man in his early 60s with ES-SCLC receives first-line atezolizumab/carboplatin/etoposide followed by maintenance lurbinectedin/atezolizumab (18:46) Case: A woman in her mid 70s with ES-SCLC expe...
Jun 18, 2026•25 min
Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics: Introduction (0:00) Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA Evaluation — Dr Friedlander (3:53) Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC — Dr Petrylak (26:41) CME information and select publications...
Jun 18, 2026•49 min
Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics: Introduction (0:00) Strategies to Identify Patients with HER2-Positive Gynecologic Cancers — Dr Liu (2:52) Available Data with and Practical Application of HER2-Targeted Therapy in Advanced Gynecologic Cancers — Dr Slomovitz (25:16) Identification and Management of Adverse Events with Trastuzumab Deruxtecan — Dr O'Malley (1:00:31) CME information and...
Jun 17, 2026•1 hr 28 min
Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics: Introduction (0:00) Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47) Noncovalent Bruton Tyrosine Kinase Inhibitors and Other Novel Strategies — Dr Kittai (38:14) CME information and select publications
Jun 16, 2026•55 min
Featuring perspectives from Dr Neeraj Agarwal, Dr Elisabeth I Heath, Dr Daniel P Petrylak, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Heath, including the following topics: Introduction (0:00) Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Shore (2:12) Current Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Petrylak (27:54) Current and Future Role of PARP Inhibitors for Metastatic Prostate Cancer (mPC) — Dr Agarwal (50:49) Emerging Role of AKT Inhib...
Jun 16, 2026•1 hr 58 min
Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics: Introduction (0:00) Antibody-Drug Conjugates and Other Novel Strategies for the Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Prof Salles (7:05) Current and Future Role of Monoclonal and Bispecific Antibodies in the Management of DLBCL — Dr Patel (26:21) Chimeric Antigen Receptor (CAR) T-Cell Therapy for DLBCL — Dr Kamdar (43:12) CAR T-Cell Therapy for Follicular Lymphoma (F...
Jun 15, 2026•2 hr
Featuring perspectives from Dr Eileen M O'Reilly and Dr Philip A Philip, including the following topics: Introduction (0:00) Optimal Incorporation of Chemotherapy into the Management of Advanced Pancreatic Cancer — Dr Philip (7:27) Other Available and Emerging Novel Approaches for Pancreatic Cancer — Dr O'Reilly (28:05) CME information and select publications
Jun 15, 2026•45 min
Featuring perspectives from Dr Thomas E Hutson, Dr Erik A Singer and Dr Ulka Vaishampayan, moderated by Dr Hutson, including the following topics: Introduction (0:00) Current Indications for Adjuvant Immune Checkpoint Inhibitor Therapy in the Management of Renal Cell Carcinoma (RCC) — Dr Singer (2:32) Potential Role of Hypoxia-Inducible Factor-2 Alpha Inhibitors as a Component of Adjuvant Treatment — Dr Hutson (30:53) Tolerability of Current and Emerging Adjuvant Approaches for RCC — Dr Vaishamp...
Jun 13, 2026•1 hr 29 min
Featuring perspectives from Dr Sara A Hurvitz and Dr Virginia Kaklamani, including the following topics: Introduction: Which Biomarkers and When (0:00) Optimizing First-Line Therapy for Patients with Hormone Receptor (HR)-Positive Metastatic Breast Cancer (mBC) (5:31) SERENA-6 Trial (19:44) Inavolisib (23:08) Management of HR-Positive mBC Progressing on a CDK4/6 Inhibitor and Endocrine Therapy (31:46) Selective Estrogen Receptor Degraders (41:15) AKT (46:13) CME information and select publicatio...
Jun 11, 2026•58 min
